SPORE preliminary applications being accepted through July 23

Details

Preliminary applications are being accepted through July 23 for those interested in applying for a UAB SPORE breast cancer grant.

All interested investigators are encouraged to send their two-page preliminary application to Carolyn Maddox. The amount of the CDA and pilot project awards is up to $50,000, and the project should be completed within a year, although a second year of funding is available after competitive renewal. 

The competitive process for these proposals is two tiered as follows:

Tier one: A two-page preliminary application outlining objectives, specific aims, significance and brief methodology is due by July 23. Also include a four-page biographical sketch, a cover page with the title of the proposed project, the type of award to which you are applying (i.e. pilot project: CDA), your name, department and contact information. The Breast SPORE leadership will review the preliminary applications by Aug. 15.

Tier two: Applicants are asked to submit an NIH-formatted full grant (PHS 398/2590 (Reb. 11/07)) by Sept. 12. The applications must include the NIH face page, abstract page, table of contents, detailed budget for initial budge period, budget for entire proposed period including the budget justification section, four-page biographical sketch and research plan. The research plan should be limited to eight pages in length including graphs and figures. A committee of UAB Breast SPORE investigators will make the final selection of grant recipients in late September with funding effective Oct. 1.

The UAB SPORE in Breast Cancer provides funding for developmental research projects and career development award. These projects must demonstrate relevance to breast cancer and can be in the areas of prevention and control, clinical pilot projects or basic science.

Projects that will enhance the understanding of the molecular biology and pathogenesis of the disease, while providing opportunities for translation into the clinical setting are of particular interest. In addition, the development of a transgenic or carcinogenic induced animal model is of prime importance.

Any questions concerning the submission of proposals should be directed to Carolyn Maddox.